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Rationale Patients with acute ischemic stroke and hyperglyce-
mia have worse outcomes than those without hyperglycemia.
Intensive glucose control during acute stroke is feasible and
can be accomplished safely but has not been fully assessed for
efficacy.
Aims The Stroke Hyperglycemia Insulin Network Effort trial
aims to determine the safety and efficacy of standard vs.
intensive glucose control with insulin in hyperglycemic acute
ischemic stroke patients.
Design This is a randomized, blinded, multicenter, phase III
trial of approximately 1400 hyperglycemic patients who
receive either standard sliding scale subcutaneous insulin
(blood glucose range 80–179 mg/dL, 4·44-9·93 mmol/L) or con-
tinuous intravenous insulin (target blood glucose 80–130 mg/
dL, 4·44-7·21 mmol/L) for up to 72 h, starting within 12 h of
stroke symptom onset. The acute treatment phase is single
blind (for the patients), but the final outcome assessment is
double blind. The study is powered to detect a 7% absolute
difference in favorable outcome at 90 days.
Study outcomes The primary outcome is a baseline severity
adjusted 90-day modified Rankin Scale score, defined as 0, 0–1,
or 0–2, if the baseline National Institutes of Health Stroke Scale
score is 3–7, 8–14, or 15–22, respectively. The primary safety
outcome is the rate of severe hypoglycemia (<40 mg/dL,
<2·22 mmol/L).
Discussion This trial will provide important novel informa-
tion about preferred management of acute ischemic stroke
patients with hyperglycemia. It will determine the potential
benefits and risks of intensive glucose control during acute
stroke.
Key words: acute ischemic stroke, cerebral infarction, clinical trial,
hyperglycemia, protocols
Introduction and rationale
Hyperglycemia is seen in approximately 40% of acute ischemic
stroke patients (1,2) and is associated with worse clinical out-
comes (1–3). Preclinical and clinical data suggest a potential clini-
cal benefit of intensive glucose control in the setting of acute
cerebral ischemia. However, hypoglycemia, especially severe or
prolonged hypoglycemia, is of greatest concern with insulin
therapy (4–7). A protocol minimizing severe and prolonged
hypoglycemia while controlling hyperglycemia has the potential
to improve outcomes in acute stroke patients. Intensive glucose
control with intravenous (IV) insulin therapy has been found to
improve clinical outcomes in some nonstroke acute illnesses
(8,9). However, there remains clinical equipoise about how best to
treat hyperglycemia during acute ischemic stroke. Results from
the National Institutes of Health (NIH)-National Institute of
Neurological Disorders and Stroke (NINDS) funded Treatment of
Hyperglycemia in Ischemic Stroke (10) and the Glucose Regula-
tion in Acute Stroke Patients (11) trials demonstrated safety and
feasibility of insulin infusion therapy for intensive glucose control
in acute ischemic stroke patients. No previous trial has fully
assessed the efficacy of intensive glucose control, and current
stroke guidelines therefore emphasize the need for definitive clini-
cal trials to determine the optimal management of hyperglycemia
in acute stroke (12).
As improved glucose control protocols decreased the risk of
hypoglycemia, determining the efficacy and safety of intensive vs.
standard glucose control in acute ischemic stroke patients became
a priority. Numerous previous glucose control trials informed the
Stroke Hyperglycemia Insulin Network Effort (SHINE) trial
design (10,11,13–15). The SHINE trial was designed to address
the key questions about hyperglycemia management in acute
stroke. The primary aim of the SHINE trial is to determine the
efficacy of intensive vs. standard glucose control. The secondary
aim is to assess safety and therefore determine an overall risk/
benefit profile for the intensive insulin intervention vs. the stan-
dard treatment. The results of this trial will likely clarify the
preferred treatment and guide clinical decision making.
Design
Stroke Hyperglycemia Insulin Network Effort is a randomized,
blinded, multicenter, controlled, phase III trial of continuous
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intravenous insulin vs. standard subcutaneous (SQ) insulin in
acute ischemic stroke with hyperglycemia. Additional treatments
constituting usual care are allowed, including IV tissue plasmino-
gen activator (tPA), intra-arterial tPA, and United States Food and
Drug Administration (FDA) cleared endovascular devices.
Throughout the study period, current American Heart Associa-
tion guideline for the early management of adults with ischemic
stroke will be followed (12).
Enrollment must be within 12 h of stroke symptom onset.
Also, to maximize early treatment, enrollment should be
within three-hours of arrival to the Emergency Department.
The 12-h window for enrollment is based on a combination of
supporting animal model data, feasibility, and generalizability
considerations.
The trial is single blind during treatment and double blind for
the functional outcome assessment. Blinding the treating team
during treatment was felt to impose excessive risk, and having an
unblinded investigator manage the study treatment for 72 h on an
hourly basis is not feasible.
At six-weeks, serious adverse events and early follow-up infor-
mation are assessed by telephone. At three-months, the primary
and secondary outcomes are assessed in person. Subjects unable
to return in person at three-months are assessed by telephone.
The sliding dichotomy that assesses the primary outcome allows
individual patients to have favorable outcomes according to
their initial stroke severity, based on the National Institutes of
Health Stroke Scale (NIHSS) (16). This design maximizes the
generalizability of the results by enrolling a broad range of
stroke severities and increases the use of individual patient
data that are often lost with single dichotomized outcome defi-
nitions. The sliding dichotomy has been successfully used in a
previous stroke trial (17) and is described under primary
outcome.
Recruitment is aimed at capturing a broad patient population
from across the United States with expected suitable representa-
tion of women and minorities. Only adults aged 18 years or older
are included. To optimize recruitment, the SHINE research team
includes a recruitment Principal Investigator (PI) (C. E. H.) and a
NINDS recruitment specialist whose focus is to maximize timely
recruitment across all sites. This team has developed individual-
ized screening and recruitment goals and a monitoring plan for
each site. The recruitment plan is designed to promptly and accu-
rately estimate the number of sites required to complete recruit-
ment on schedule.
The limitations of this design include potential bias due to the
single-blind acute treatment period. The double-blind primary
outcome assessment is designed to eliminate this bias. Potential
measured and unmeasured confounders include all treatments
and care outside the study treatment protocol through the 90-day
outcome assessment. The secondary analysis will attempt to
adjust for prespecified confounds.
Patient population
The primary target population for the SHINE trial is acute
ischemic stroke patients likely to have persistent hyperglycemia
during hospitalization and who can be enrolled within 12 h of
symptom onset (Table 1). Patients receiving standard IV tPA are
stratified at randomization to prevent confounding of treatment
effect.
Previous data indicate that patients with history of type 2 dia-
betes or those with baseline blood glucose at or above 150 mg/dL
(8·32 mmol/L) (even without diabetes) are likely to have persis-
tent hyperglycemia, unless treated with insulin (10,11,13,18).
Patients who do not meet these criteria typically have self-limited
Table 1 Eligibility criteria
Inclusion
1. Age 18 years or older.
2. Clinical diagnosis of ischemic stroke. Neuroimaging must be done to exclude intracranial haemorrhage.
3. Protocol treatment should begin within three-hours after hospital arrival and within 12 h after stroke symptom onset. If time of symptom
onset is unclear or patient is awakening with stroke symptoms, the time of onset will be the time that the patient was last known to be
normal.
4. Known history of type 2 diabetes mellitus and admission blood glucose >110 mg/dL (>6·10 mmol/L) OR admission blood glucose
150 mg/dL (8·32 mmol/L) in those without known diabetes mellitus.
5. Baseline NIHSS score 3–22.
6. Prestroke modified Rankin Scale score = 0 (able to walk, look after own affairs, and no residual symptoms from prior stroke).
7. Able to provide a valid informed consent to enroll (self or legally authorized representative).
Exclusion
1. History of type 1 diabetes mellitus.
2. Substantial preexisting neurological or psychiatric illness that could confound the neurological or other outcome assessment.
3. Having received experimental therapy for the enrollment stroke. IV tPA up to 4·5 h or IA tPA are allowed as are endovascular therapies using
FDA cleared devices. Non-FDA cleared devices are considered experimental and are excluded.
4. Known to be currently pregnant or breast-feeding.
5. Unlikely to survive 90 days due to another serious condition.
6. Inability to follow the protocol or return for the 90-day follow-up.
7. Renal dialysis, including haemo- or peritoneal.
FDA, Food and Drug Administration; IA, intra-arterial; IV, intravenous; NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen
activator.
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hyperglycemia that resolves early and spontaneously during hos-
pitalization (10,13,19). Thus, the SHINE eligibility criteria
attempt to exclude patients with self-limited hyperglycemia.
Previous data show that patients with the mildest strokes
generally have good outcomes and those with the most severe
strokes generally have poor outcomes. Therefore, the mildest
(NIHSS < 3) and most severe (NIHSS > 22) stroke patients
are excluded from the SHINE trial to avoid obscuring a
treatment difference between the groups. Also excluded are
patients for whom clinical equipoise for treatment is absent
(e.g., those with type 1 diabetes or pregnancy), those at
excessive risk from either intervention (e.g., receiving renal
dialysis), those at risk for loss to follow-up (inability to return),
and those with confounding that would preclude accurate esti-
mation of treatment effect (other experimental interventions,
substantial preexisting neurological or psychiatric disease)
(Table 1).
Additionally, as with the sliding dichotomy some patients
require a 90-day mRS of 0 to classify as having favorable outcome,
those with residual symptoms from prior stroke or who are
unable to live independently due to preexisting disabilities are
excluded from this trial.
Randomization
The SHINE trial utilizes a web-based central randomization
system that employs a combination of covariate balance (20)
and response adaptive randomization (RAR) (21) methods. The
prognostic variables considered at the time of randomization
include baseline NIHSS strata (3–7,8–14,15–22), use of IV tPA
thrombolysis (yes/no), and clinical center. Randomization is ini-
tially 1:1, but as the trial progresses this ratio may change based
on two factors, the prevention of serious imbalances in the pre-
specified prognostic variables and the favorable outcome rate in
each treatment group. This randomization design is aimed to
preserve the randomness of treatment assignment, prevent
serious imbalance in important baseline prognostic variables,
and promote subject recruitment while preserving the statistical
test power.
Treatment
There are two treatment groups in the SHINE trial (Table 2). One
group receives continuous IV insulin infusion to maintain blood
glucose of 80–130 mg/dL (4·44–7·21 mmol/L). An FDA cleared
computerized decision support tool, GlucoStabilizer® (22) [Alere
Informatics Solutions (AIS), Charlottesville, VA, USA], recom-
mends the insulin drip rate to maintain the glucose in the target
range. The other group receives only SQ insulin to maintain blood
glucose of 80–179 mg/dL (4·44–9·93 mmol/L) (Table 2). The
glucose values are based on point of care capillary glucose testing.
All patients are treated with a combination of IV and SQ study
medications, some of which are insulin and some are normal
saline to maintain the blind (Table 2). All prestroke antidiabetes
medications are held throughout the treatment period. All
patients are treated in hospital units that support IV insulin infu-
sion. At the completion of the 72-h study treatment period, the
treating team determines the subsequent standard care regimen.
For patients who are ready for discharge prior to 72 h, the study
medications are discontinued at least six-hours prior to discharge.
If study treatment must be temporarily interrupted for standard
care reasons, procedures for pausing and restarting the study
treatment are provided.
The treating nurses enter all glucose levels and insulin treat-
ments in both groups into laptop computers, which are instantly
transmitted to an AIS server in Charlottesville, VA, USA. AIS
transfers all study data to the Statistical and Data Management
Center every 24 h.
Hypoglycemia is defined as blood glucose <70 mg/dL
(<3·88 mmol/L) and severe hypoglycemia as <40 mg/dL
(<2·22 mmol/L), but to prevent hypoglycemia, study medications
are held and IV glucose is given in both groups whenever the
blood glucose levels fall to <80 mg/dL (<4·44 mmol/L). In the
control group, patients receive 25 mL of 50% dextrose (D50),
glucose level is rechecked every 15 min, and additional D50
Table 2 Outline of subcutaneous and intravenous study treatments in the SHINE protocol
Control group Intensive treatment group
Subcutaneous
treatments
Regular human insulin at 6:00, 12:00, 18:00, and 24:00
according to sliding scale
At 24 and 48 h advance to the next treatment level if the latest
two glucose levels are 180 mg/dL
Level 1 sliding scale: 2–8 units for glucose 180 to >450 mg/dL
Level 2 sliding scale: 4–16 units for glucose 180 to >450 mg/dL
Level 3 sliding scale: same as level 2 plus long-acting basal insulin
(glargine*) at 48 h
If not eating or continuous tube feeding, normal
saline (placebo) at 9:00 and 21:00
or
If eating or bolus tube meals, rapid acting analog
insulin with meals
Intravenous treatments Normal saline (placebo) with periodic rate adjustments Continuous regular human insulin according to a
computerized tool, GlucoStabilizer®
Capillary blood glucose
monitoring
Every one-hour for the first four-hours, then 3:00, 6:00, 9:00,
12:00, 15:00, 18:00, 21:00, and 24:00 (before meals if patient
is eating)
Every one- to two-hours according to
GlucoStabilizer® instructions
*Dose of glargine insulin is 40% of the total insulin given in the prior 24 h.
SHINE, Stroke Hyperglycemia Insulin Network Effort.
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is given after each check until the glucose is 80 mg/dL
(4·44 mmol/L). In the intervention group, the GlucoStabilizer®
program recommends a calculated dose of D50 based on the
blood glucose level (22). The computer sounds an alarm
to recheck the glucose level every 15 min and recommends
additional D50 doses until the glucose is 80 mg/dL
(4·44 mmol/L).
When blood glucose is <70 mg/dL (<3·88 mmol/L) in either
group, a confirmatory blood sample is sent to the laboratory.
Additionally, a hypoglycemia symptomatic questionnaire (23)
and a neurological examination are done every 15 min until
resolution.
Primary outcome
The primary efficacy outcome is baseline severity adjusted 90-day
mRS assessed using a sliding dichotomy to identify favorable out-
comes, also known as responder analysis (16). The responder
analysis dichotomizes mRS scores as favorable or unfavorable
based on the baseline NIHSS measured at enrollment and the
90-day mRS and was chosen to provide a more sensitive measure
of clinical effect. Patients in the lowest baseline severity tertile
(NIHSS 3–7) need to have a 90-day mRS score of 0 to achieve
favorable outcome. Patients with baseline NIHSS 8–14 can have a
90-day mRS score 0–1 for favorable outcome, and those with
baseline NIHSS 15–22 can have a 90-day mRS score 0–2 for
favorable outcome, as used in previous trials (17).
Secondary outcomes
Secondary outcomes include favorable outcome as measured by
the NIHSS, Barthel Index, and the Stroke Specific Quality of Life
scale (24) at 90 days. Blood glucose control and protocol adher-
ence will also be analyzed.
Data and safety monitoring
Adverse events are collected during the study treatment period,
and serious adverse events are collected throughout the entire
study period. The primary safety outcome is the rate of severe
hypoglycemia determined as the percentage of patients in each
group having at least one blood glucose measurement <40 mg/dL
(<2·22 mmol/L) during the treatment period.
A study appointed independent safety monitor and an NIH-
NINDS appointed Data and Safety Monitoring Board (DSMB)
oversee safety in the SHINE trial. The DSMB meets every six-
months to review study progress and accumulated data. Their
main responsibilities are to ensure that study participants are not
exposed to unnecessary or unreasonable risks and that the study is
conducted with high scientific and ethical standards. The DSMB
is assisted by an independent safety monitor who reviews and
adjudicates all serious adverse events throughout the study. The
independent safety monitor also fields safety concerns from the
investigators during study treatment.
Sample size
The sample size estimate was based on data from the two NIH
funded pilot trials (10,11), as well as other relevant acute stroke
trials (25,26). These data supported an estimate of 25% favorable
outcome rate in the control group. The minimal clinically rel-
evant absolute difference in favorable outcome between the two
treatment groups was estimated to be 7% (control group = 25%;
intervention group = 32%). The study is therefore powered to
detect an absolute 7% difference in favorable outcome between
the groups. The study design includes four interim analyses for
both efficacy and futility of the primary outcome (after 500, 700,
900, and 1100 patients complete the study) and a final analysis for
a total of five planned analyses of the primary outcome. Including
a 3% nonadherence rate and the four interim analyses, approxi-
mately 1400 randomized patients are needed to provide 80%
power with a two-sided type I error rate of 0·05.
In the event that the control group favorable outcome rate is
higher than 25%, a blinded sample size reestimation will be done
prior to the first interim efficacy/futility analysis using the
approach of Gould and Shih (27). The overall favorable outcome
rate of the study population will be estimated using the interim
data for the sole purpose of sample size reestimation (not for
interim testing of a treatment effect).
Statistical analysis
The primary analysis for the SHINE trial will compare the pro-
portion of subjects in each treatment group with favorable
outcome after controlling for baseline NIHSS and standard IV
tPA. Outcome differences will be analyzed under the intention-
to-treat principle (all randomized participants included) and
adjusted relative risks will be reported with two-sided 95% con-
fidence intervals. Additional analyses will identify potential prog-
nostic variables as covariates for secondary analyses of the
primary outcome. Specific variables include age, gender, race
ethnicity, race-ethnicity, admission blood glucose, previous
stroke, lacunar stroke sub-type, and time from stroke onset to
randomization.
The four interim analysis plans described above use the error
spending function method with O’Brien and Fleming (OBF)-type
stopping guidelines (28,29). The OBF-type boundary is consid-
ered conservative as its boundaries make it unlikely to terminate
a study early by requiring overwhelming early evidence of efficacy
or futility. It spends smaller amounts of alpha at the first look and
gradually increases the spending as more information is acquired
while maintaining the overall type I and II error rates. For
example, under the null hypothesis of no difference between the
two treatment groups, there is a 4% chance of stopping the trial
for futility at the first look, 10% at the second, 25% at the third,
and 35% at the fourth. Overall, there is approximately a 75%
chance of stopping the trial early for futility if there is no differ-
ence. Under the alternative hypothesis, there is an 11% chance of
stopping the trial early for overwhelming efficacy at the first look
and a 66% chance overall of stopping early. These analyses will
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begin once final outcome data are available from roughly one-
third of the study population.
Trial organization and funding
The SHINE trial is funded by the NIH/NINDS. Recognizing the
effort and skill needed to successfully run the various aspects of a
large acute clinical trial, the SHINE trial has three principal inves-
tigators, each with a specified focus. The administrative PI (K. C.
J.) is the main contact person for SHINE and chairs the executive
committee. The protocol PI (A. B.) oversees the treatment proto-
cols. The recruitment PI (C. E. H.) is focused on patient recruit-
ment and retention. A study endocrinologist (R. J.) oversees the
insulin treatments and all relevant metabolic issues. The SHINE
trial is conducted primarily in collaboration with the NINDS
funded Neurological Emergencies Treatment Trials (NETT)
Network, as well as numerous ancillary (non-NETT) sites for
patient enrollment. The NETT includes 22 hub and spoke com-
plexes (Appendix) (NETT PI is W. G. B.). The Clinical Coordi-
nating Center for the NETT and therefore SHINE is at the
University of Michigan. The Statistical and Data Management
Center for the NETT and for SHINE is the Medical University of
South Carolina Data Coordinating Unit, directed by the SHINE
Statistical PI (V. L. D.). A total of approximately 60 sites are
expected to participate in this trial.
Summary
The SHINE trial is designed to address key questions about the
management of hyperglycemia during acute ischemic stroke. This
trial has the potential to impact the management of a substantial
proportion of acute stroke patients. This trial design is scientifi-
cally rigorous, including RAR and baseline severity adjusted
double-blind primary outcome assessment. Continuous intrave-
nous insulin infusion based on a computerized decision support
tool will be compared with a standard SQ insulin sliding scale.
Recruitment started in April 2012 and is expected to be completed
in 2016.
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Addendum
After enrolling 57 patients the SHINE DSMB approved a protocol
modification allowing enrolment of patients with a pre-stroke
mRS of 0 or 1 if their baseline NIHSS is 8–22. However, patients
with baseline NIHSS 3–7 must have a pre-stroke mRS of 0 to
permit reaching a potential favorable outcome that is based on a
sliding dichotomy of the mRS according to the baseline NIHSS
score.
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